In a filing, Sagimet Biosciences Inc revealed its President & CEO Happel David unloaded Company’s shares for reported $0.6 million on Jul 21 ’25. In the deal valued at $9.13 per share,65,478 shares were sold. As a result of this transaction, Happel David now holds 689,722 shares worth roughly $5.83 million.
Then, Martins Eduardo Bruno sold 8,277 shares, generating $75,607 in total proceeds. Upon selling the shares at $9.13, the Chief Medical Officer now owns 106,936 shares.
Before that, Rozek Elizabeth sold 10,780 shares. Sagimet Biosciences Inc shares valued at $98,471 were divested by the General Counsel and CCO at a price of $9.13 per share. As a result of the transaction, Rozek Elizabeth now holds 183,726 shares, worth roughly $1.55 million.
Canaccord Genuity initiated its Sagimet Biosciences Inc [SGMT] rating to a Buy in a research note published on July 24, 2025; the price target was $28. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. UBS began covering SGMT with “Buy” recommendation on November 12, 2024. Goldman revised its rating on June 28, 2024. It rated SGMT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of SGMT
On Monday, Sagimet Biosciences Inc [NASDAQ:SGMT] saw its stock jump 2.42% to $8.45. Over the last five days, the stock has lost -17.40%. Sagimet Biosciences Inc shares have risen nearly 151.49% since the year began. Nevertheless, the stocks have risen 87.78% over the past one year.
How much short interest is there in Sagimet Biosciences Inc?
A steep rise in short interest was recorded in Sagimet Biosciences Inc stocks on 2025-07-15, dropping by -0.43 million shares to a total of 3.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.81 million shares. There was a decline of -12.66%, which implies that there is a negative sentiment for the stock.
